BD Facsaria for use in BSL3

描述（由申请人提供）：新泽西医学院（NJMS）是大量临床和基础科学家的家园，他们都致力于通过开发新的候选疫苗，新药和快速诊断来减轻结核病（TB）的全球健康问题。如果NJMS生物安全三级（BSL3）设施能够分选活的结核分枝杆菌（Mtb）感染细胞和活的结核分枝杆菌，这些结核病研究人员的研究计划将大大受益。为了在校园里获得BSL3设施的这一资源，六位高生产力和NIH资助的研究人员联合起来提交了这一共享仪器拨款提案，以购买BD FACSAria II细胞分选器。由于活体结核分枝杆菌研究的生物危害性，需要一种“专用”仪器。新的FACSAria将被安置在NJMS新发和再发病原体中心的BSL3设施中，并将由经验丰富的流式细胞仪技术人员Angelika Batista女士操作和维护。首席研究员Padmini Salgame博士将提供科学监督，流式细胞仪核心设施的科学主任Patricia Fitzgerald-Bocarsly博士将提供行政监督。最初，FACSAria将主要由NJMS的6名结核病研究人员组成的申请小组使用。然而，我们预计该仪器的使用量将增加，因为预计在不久的将来将招募新的结核病调查员到NJMS。BD FACSAria细胞分选机是一种台式分选机，因此方便BSL3外壳。该仪器不需要特殊的房间要求或多年的技术专业知识即可完全操作。操作简单，在高速细胞分选和多色分析中具有优异的性能。独立的流体车提供空气压力和真空，消除了外部源的需要。这一特点使该仪器可以很容易地适应在BSL3设施中使用，而不需要传统高速流式细胞仪的特殊和昂贵的设施要求。BD“气溶胶管理选项（AMO）”是一种在分选室区域内提供额外气溶胶管理和清除的设备。全面的分类监测和堵塞检测是标准的集成软件功能，使FACSAria细胞分选机易于使用。总的来说，FACSAria非常适合在BSL3设施中操作，用于分选受感染的细胞和细菌。公共卫生相关性：结核病仍然是对全球健康的严重威胁，耐多药结核病在世界许多地方正在达到危机的程度。该小组的研究小组的共同研究重点是开发候选疫苗、新药和诊断方法，以帮助减轻全世界的结核病负担。这些研究人员的研究包括从感染结核分枝杆菌的动物中分离和分析活细胞以及对活结核分枝杆菌进行分类。如果获得BSL3设施的“专用”高速流式细胞仪，他们项目的成功将大大增强。

DESCRIPTION (provided by applicant): The New Jersey Medical School (NJMS) is home to a large number of clinical and basic scientists all working towards the common goal of mitigating the global health problem from Tuberculosis (TB) through the development of novel vaccine candidates, new drugs and rapid diagnostics. The research program of several of these TB investigators would greatly benefit if access to sorting viable M. tuberculosis (Mtb)-infected cells and live M. tuberculosis bacteria is available in the Biosafety Level 3 (BSL3) facility at NJMS. Toward achieving this resource for the BSL3 facility on campus, six highly productive and NIH funded investigators have joined together to submit this Shared Instrument Grant proposal for the purchase of a BD FACSAria II cell sorter. Due to the biohazardous nature of live M. tuberculosis studies a "dedicated" instrument is requested. The new FACSAria will be housed in the BSL3 facility in the Centre for Emerging and Re-emerging Pathogens at NJMS and will be operated and maintained by an experienced flow cytometry technician, Ms. Angelika Batista. The Principal Investigator, Dr. Padmini Salgame will provide scientific oversight and Dr. Patricia Fitzgerald-Bocarsly, Scientific Director of the Flow Cytometry Core facility will provide administrative oversight. Initially, the FACSAria will be primarily utilized by the applicant group of six TB researchers at NJMS. However, we anticipate increased usage of the instrument since new TB investigators are expected to be recruited to NJMS in the near future. The BD FACSAria cell sorter is a benchtop sorter and is thus convenient for BSL3 housing. This instrument does not require special room requirements or years of technical expertise to be fully operational. It is easy to operate and provides superior performance in high-speed cell sorting and multicolor analysis. The self-contained fluidics cart supplies air pressure and vacuum eliminating the need for an external source. This feature allows the instrument to be readily adapted for use in the BSL3 facility without the special and costly facility requirements of a traditional high-speed flow cytometer. The BD" Aerosol Management Option (AMO) is a device that provides additional aerosol management and removal within the sort chamber area. Comprehensive sort monitoring and clog detection are standard integrated software features that make the FACSAria cell sorter easy to use. Overall, the FACSAria is extremely well suited for operation in a BSL3 facility for sorting infected cells and bacteria. Public Health Relevance: Tuberculosis remains a serious threat to global health and multi drug resistant TB is reaching crisis proportions in many parts of the world. The assembled team of investigators of this SIG has a common research focus in developing vaccine candidates, novel drugs and diagnostics that will aid in reducing the TB burden world wide. The research of these investigators involves isolation and analysis of viable cells from M. tuberculosis-infected animals and sorting of live M. tuberculosis bacteria. The success of their program would be greatly enhanced with the acquisition of a "dedicated" high speed Flow Cytometer in the BSL3 facility.